In the preceding communication (1) evidence was described indicating that the fecal dipyrrylmethene or "fuscin" compounds are derived mainly from anabolic sequences on the pathway to heme, rather than oxidative schism of tetrapyrryl bilirubinoids from destroyed hemoglobin. Using N15 glycine, it was shown that N15 was rapidly incorporated in mesobilifuscin (Mbf) with production of an early peak and that there was little or no significant concentration of N" in Mbf at the time of destruction of mature circulating erythrocytes when the stercobilin N15 was greatly elevated. It is recognized, however, that under appropriate conditions Mbf is derived by oxidation of bilirubinoid compounds and that minor fractions of the dipyrrylmethene group in the excreta may originate in this fashion. Under normal conditions the feces contain chromogens and pigments of both anabolic and catabolic origin, i.e., compounds of mesobilifuscin(ogen) type elaborated principally during heme synthesis, and urobilinogen derived, at least mainly, from hemoglobin destruction. It would be anticipated, therefore, that the amount of fecal Mbf as compared with urobilinogen might vary significantly in differing hematologic disorders.
The present study was undertaken to compare the excretion of mesobilifuscin and urobilinogen in the feces of normal subjects and in patients with various anemias.
MATERIALS AND METHODS
A total of 140 individuals were studied. Of these, 19 were normal subjects, either medical or nursing students or hospital personnel. The remainder comprised 32 patients with hemolytic anemia, four with megaloblastic anemia, nine with hyporegenerative anemia, nine with anemia due to rheumatoid disease, 27 with anemia * Aided under contracts with the Surgeon-General's Office, United States Army. due to various other causes including infection, uremia, iron deficiency, cancer and refractory anemia, 20 with parenchymal liver disease including cirrhosis and hepatitis and 20 with obstructive biliary tract disease.
Collections of feces were made over four or eight day periods in the majority of instances, although in 44, as will be indicated, random or short period samples were analyzed for urobilinogen and mesobilifuscin. Where the four day collection was adequate (at least 350 Gm.) the per diem amount was calculated; otherwise the values are given in mg. per 100 Gm. Urobilinogen was determined by the method of Schwartz, Sborov and Watson (2) . After extraction of the urobilinogen from the initial acidified filtrate, the latter was used for determination of Mbf. The method was the modification of Siedel and M6ller's procedure (3) described in the preceding paper for isolation of Mbf. Following elution of the methyl ester from the A1205 column, the hot glacial acetic acid eluate was filtered and diluted. The optical density of this solution was then determined in the Evelyn colarimeter using a 490 filter. The standard was prepared from mesobilirubinogen by oxidation with lead tetraacetate as described by Siedel and Moller (3) . In the preceding paper of this series it was shown that the fecal pigment obtained with this method corresponds fully with Siedel and M6ller's fecal mesobilifuscin in terms of solubility and chromatographic behavior, spectral characteristics, nitrogen percentage and products of oxidative degradation. For purposes of determining the reproducibility of results with this method, multiple analyses for Mbf were performed by different technicians on fecal samples from six subjects (Table I ). The individual variation in urobilinogen and Mbf excretion was examined by analyses of multiple four day samples in 15 subjects, multiple short period samples in three subjects and four day samples followed by one or more short period samples in three subjects (see under Results).
Red blood cell survival was studied in 43 cases using Cr' according to the ascorbic acid modification (4) of the usual method (5-7). Sternal bone marrow aspiration studies were performed in 52 cases.' Bone marrow studies were not performed in any of the normal subjects; (9) . In two cases the urine bilirubin was quantitated by the method of Malloy and Evelyn (10) .
RESULTS
The values obtained for fecal urobilinogen, fecal mesobilifuscin, the urobilinogen/mesobilifuscin (U/Mbf) ratio, the T1/2 of Cr51 and the myeloiderythroid volume and percentage of normoblasts Figure   1 . In the group of normal subjects (Table II) the average daily excretion of urobilinogen was lower than previously reported from this laboratory (11) . This may be explained, at least in part, by the inclusion of a greater number of female subjects in whom the red cell mass and, consequently, the urobilinogen excretion are normally less than in the male. The average daily excretion of Mbf and the U/Mbf ratio ranged, respectively, from (Table II) and thirteen patients (Tables III  through VI) are seen. However, the U/Mbf ratio remained relatively constant in a given individual, varying no more than 2.2 in 20 of 21 subjects with multiple determinations. The one exception (Case 60) will be considered again in the following.
The T1/2 of Cr5' of 25 to 29.5 days in the normal subjects (Table II) agrees with previous reports using the same method (12) . The myeloiderythroid volume in the bone marrow ranges from 5 to 8 per cent normally, and the normal percentage of normoblasts is considered to be approximately 20 (8) .
A sharp contrast to the findings in normal subjects is seen in patients with hemolytic anemia (Table III and Figure 1 ). In most of these cases the fecal urobilinogen was elevated; however, in eight of 32 patients the urobilinogen was less than 300 mg. per day. In the latter cases the hemoglobin levels were considerably decreased; when urobilinogen values were calculated in relation to the total circulating hemoglobin as "apparent wastage" (13, 14) , they were found to be significantly elevated. It t The values in brackets relate to determinations on a series of four day collections for which the average value is given at the left. two patients studied; this appears to agree with earlier observations (13, 14) and with the findings of London and West using N15 (15) .
Values for fecal Mbf in patients with hyporegenerative anemia (Table IV, Figure 1) Table VII. plastic; this will be considered again in the following.
In the presence of parenchymal liver disease (cirrhosis or hepatitis) the values for fecal Mbf were usually low, while the urobilinogen showed considerable variation. In the 20 patients in this series (Table VI, Figure 1 ) the values for fecal urobilinogen were within the normal range in eight, slightly elevated in three and decreased in nine. However, fifteen cases showed definitely reduced values for Mbf and three of the remainder were at the lower limit of the normal range. This disproportionate decrease of Mbf was reflected in the U/Mbf ratio which was quite high in 17 cases. The U/Mbf ratio was normal in one case and definitely low in two. In the latter cases (Nos. 106 and 116) Mbf excretion was normal but urobilinogen was disproportionately decreased. Of interest are the red cell survival studies in six cases. The T1/2 of Cr5' was in the hemolytic range (12 days) in one patient (No. 84); uro- bilinogen was slightly elevated in this case (311 mg. per day), but Mbf was markedly decreased (1.0 mg. per day). In the other five cases the T1/2 of Cr5l was moderately shortened (17 to 24 days), but the urobilinogen was not elevated. These findings are in accord with the earlier study of Jones, Weinstein, Ettinger and Capps ( 16) .
In marked contrast to the decreased fecal excretion of Mbf was the finding of increased amounts of Mbf 2 in the urine of 10 out of 11 patients as compared with seven normal subjects (Table X) . Bilirubin was present in the urine of the three patients with the greatest values for mesobilifuscin (Nos. 111 through 113). In these cases it is not unlikely that some of the pigment was bilifuscin derived by oxidation of bilirubin. No bilirubin was detected in the urine of the other seven cases, three of which, however, exhibited excesses of urobilinogen. Twenty patients with biliary obstruction were studied (Table VII, Figure 1 ). The fecal U/Mbf ratio was high in all but two of this group. In 11 the fecal urobilinogen value indicated complete biliary obstruction (< 5 mg. per day) and in 10 of these no fecal Mbf was demonstrable; (Case 101 had 3.7 mg. urobilinogen and 0.21 mg. Mbf per day). In nine cases there was incomplete biliary obstruction (urobilinogen > 5 mg. per day).
In five of these no Mbf was demonstrated in the 2Although obtained by the same adaptation of Siedel and M6ller's (3) method as applied to feces, the material thus far analyzed is obviously impure and may be complexed with a non-nitrogenous urinary constituent, as the percentage of nitrogen (4.0 to 5.0 per cent) is less than the theoretical for Mbf ester, i.e., 8.8. feces, while in the other four small quantities were present.
DISCUSSION
Evidence described in the preceding paper (1), obtained by comparison of isotope labeled fecal stercobilin (or urobilin) and mesobilifuscin, after feeding N15 glycine, indicated that the latter is derived mainly from anabolic sources. The present data are in accord with that concept.
If the fecal Mbf were derived mainly from schism of bilirubinoid compounds as formerly postulated, one might anticipate that in different disease states the fecal urobilinogen and Mbf would vary in the same direction and to about the same degree. In other words, the U/Mbf ratio would be expected to remain essentially the same. Actually, as shown in the present study, the U/Mbf ratio varies greatly in different types of disease.
On the other hand, if the dipyrrylmethene pigments such as mesobilifuscin are derived mainly from anabolic sources, then their amount might often reflect the magnitude of heme synthesis. Thus, in hemolytic anemia, where red cell production is greatly enhanced, Mbf is also increased to a marked degree, often indeed to a relatively greater extent than the urobilinogen, so that the U/Mbf ratio is low. Similarly in pernicious anemia, with its megaloblastic arrest in the bone marrow and ineffective heme synthesis (see above), the fecal Mbf is high and the U/Mbf ratio low. This is not surprising in view of the observations mentioned previously, that in this disease a large proportion of the fecal urobilinogen is also derived from sources other than mature circulating red blood cells. In the hyporegenerative or "refractory" anemia, as a rule, very little fecal Mbf is found while the urobilinogen is often normal or increased, the latter being due either to a hemolytic factor, to blood transfusions, or both. Thus, the U/Mbf ratio is often high. A striking example of this is seen in Table IX . Observations in certain other cases of anemia (Table V) also support this concept. In most of these cases the rates of erythrocyte production and destruction are in balance. Thus, the U/Mbf ratio is normal. Bone marrow studies in seven of the 11 cases with abnormal U/Mbf ratios show increased erythropoietic activity in all four cases with low U/Mbf Not determined ratios and decreased erythropoietic activity in two cases with high U/Mbf ratios. Several additional cases of anemia, not included in the Tables, have been studied recently. These have also shown a general parallelism between heme synthesis, erythropoiesis and Mbf excretion in the feces. Thus, the present data indicate that the magnitude of effective or attempted heme synthesis is more significant than hemoglobin destruction in determining the amount of fecal Mbf.
Exceptions to this rule are seen, however. In some cases Mbf is reduced and the U/Mbf ratio is high, despite apparently normal or increased erythropoietic activity. Apart from the cases of liver and biliary tract disease, these findings have been encountered in patients with rheumatoid disease (Table IV, Figure 1) , and in one patient (Case 78) with refractory anemia who had normoblastic hyperplasia of the bone marrow but no demonstrable Mbf in either feces or urine. In this situation one may consider the possibility that the immediate precursors of the dipyrrylmethene or "fuscin" compounds are being more efficiently utilized. It is conceivable that in association with an increased erythropoiesis, hemoglobin synthesis might proceed at a relatively slower rate but more efficiently so that no excess of precursors is available for Mbf formation. This would imply a more complete utilization in porphyrin synthesis, with little available for the excess dipyrrylmethene of the feces. The possibility might also be considered that some fraction of the fecal dipyrrylmethene, at least in some cases, is derived along the biosynthetic pathway to a heme other than that of the hemoglobin formed in the normoblast. It is true that in the two cases of hepatic porphyria (Nos. 76 and 77) the fecal Mbf was rather low, despite the strong likelihood that the metabolic disturbance in these cases is related to the biosynthesis of an hepatic heme or hemes, rather than hemoglobin. It is interesting to speculate that in this situation the excessive porphyrin and/or precursor formation might deplete the total "pigment pool" of the body to such an extent that Mbf elaboration related to hemoglobin synthesis might be significantly reduced. Nevertheless it is quite possible that under other abnormal circumstances there might be excessive dipyrrylmethene production unrelated to hemoglobin synthesis. In the case of lead poisoning (Case 83) with abnormal porphyrin synthesis, excessive amounts of fecal Mbf and a low U/Mbf ratio were found.
In In two cases of macroglobulinemia the findings are also at variance with each other. In one (No. 75) Mbf excretion was decreased and the U/Mbf ratio was high, while in the other (No. 92) both urobilinogen and Mbf were definitely increased and the U/Mbf ratio was normal. The bone marrow appeared hypoplastic in both. The basis of this difference is not clear.
Patients with liver disease usually excrete small amounts of fecal Mbf and exhibit high U/Mbf ratios. The ratio may be low if the fecal urobilinogen is disproportionately reduced as in Cases 106 and 116 (see above). A likely explanation of the reduced fecal Mbf is that it cannot be excreted normally by a damaged liver and is diverted to the urine. This concept is supported by the consistent increases in urinary "mesobilifuscin" noted in Table X . At the same time, comparison of the data in Tables II, VI and X reveals that the total Mbf in urine and feces in the cases of hepatic disease is often considerably greater than that encountered normally. To what extent this increase is due to oxidative schism of bilirubin or urobilinogen, possibly in the kidney or urine, or to anabolic excesses, has not been determined.
SUMMARY AND CONCLUSIONS 1. The amounts of mesobilifuscin and urobilinogen in the feces have been compared in a group of normal subjects and in cases of various types of anemia and liver disease. The results in many of the cases were further compared with erythrocyte survival and erythropoiesis, with the aid of Cr5' and bone marrow studies.
2. The range of values for mesobilifuscin in normal human feces is 7 to 18 mg. per day and that for the urobilinogen/mesobilifuscin (U/Mbf) ratio is 8 to 14.
3. Conditions associated with increased erythropoietic activity, such as hemolytic and megaloblastic anemias, were generally associated with increased fecal mesobilifuscin (Mbf) and urobilinogen (U) and normal or low U/Mbf ratios. Conversely, cases of hyporegenerative anemia usually had decreased Mbf and high U/Mbf ratios. This was also true in rheumatoid disease despite increased normoblastic activity in the bone marrow.
4. The observations summarized in Conclusion 3 accord better with the concept that the native fecal Mbf or its colorless chromogen is mainly anabolic, formed during the biosynthesis of heme, rather than a product of heme destruction and bilirubinoid schism.
5. In cases of liver disease, the fecal Mbf is disproportionately small and the U/Mbf ratio high, while the urinary (crude) Mbf is consistently elevated. The extent to which the latter represents diversion of Mbf ordinarily excreted in the bile, or derivation from bilirubin or urobilinogen in the kidneys or urine, has not been determined.
